… variants of SARS-CoV-2 with a long … SARS-CoV-2 infection in transgenic hACE2 mice.
Nb 15 -Nb H -Nb 15 is a potential candidate for both the prevention and treatment of SARS-CoV-2 …

… model of SARS-CoV-2 infection … SARS-CoV-2 infection. To determine if Fu2 could reduce
disease severity when administered in early infection, we tested its ability to neutralize the virus …

… Based on aSA3 and aRBD-2, we engineered a novel bispecific Nb dimer termed 2-3-Fc, …
In vivo assays showed that 2-3-Fc was effective in combating Omicron infection through not only …

… Eventually, we engineered a bispecific nanobody conjugate … nanobodies have led them to
be developed as potential therapeutics against viral infection, including SARS-CoV-2 infection …

… of S-RBD to inhibit SARS-CoV-2 infection. To minimize the size of the resulting bispecific
inhibitor, c19s130Fc, we chose to fuse the SARS-CoV-2 S-RBD nanobody VHH72 (44) to …

… VOC, we first performed lentivirus-based pseudovirus infection assays. Seven pseudoviruses
were produced to represent four VOC (Alpha, B.1.1.7; Beta, B.1.351; Gamma, P.1 and Delta…

… the V + E biparatopic nanobody eliminated SARS-CoV-2 infection at a dilution 62 times
higher than the individual nanobodies (22 times greater than that of individual nanobodies). This …

… on two highly efficient RBD‐specific biparatopic nanobodies that bind and neutralize
SARS‐CoV‐2 … , underscoring the potential of nanobodies to prevent or treat SARS‐CoV‐2 …

… a bispecific SARS-CoV-2 neutralizing nanobody in secretory Immunoglobulin A (SIgA) format,
named S2-3-… We and another group demonstrated that infection of SARS-2 can elicit IgA …

… for SARS-CoV-2 therapy. In this regard, fusion to the Fc region in hcAbs is a key factor for
their therapeutic efficacy in vivo against SARS-CoV-2 infections … suggested that bispecific (or …